Literature DB >> 2866578

The predominant protein in human seminal coagulate.

H Lilja, C B Laurell.   

Abstract

The predominant protein in human seminal vesicle secretion constitutes the structural protein of coagulated semen. This high molecular weight protein (HMW-SV-protein) is stable in seminal vesicle secretion during in vitro storage at 37 degrees C for at least 20 h, but is rapidly cleaved on mixing with prostatic proteases. Seminal coagulate, washed free of soluble components, is dissoluble by 2 to 3 mol/l of guanidine-HCl. Although dithiothreitol added to seminal coagulate does not liquefy the clot, complexes between HMW-SV-proteins are broken up by reduction under denaturing conditions, which suggests that the non-covalent linkages of HMW-SV-proteins are essential in the clot. Prostatic proteases cleave the HMW-SV-protein during liquefaction of ejaculated semen to a series of labile proteins. These proteins are further cleaved to peptides of successively decreasing size after completed liquefaction. The cleavage of the HMW-SV-protein is the major cause of the fast shift of the electrophoretic pattern of seminal proteins if semen is stored without protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866578     DOI: 10.3109/00365518509155271

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  13 in total

Review 1.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

2.  Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein.

Authors:  H Lilja; A Lundwall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

3.  Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.

Authors:  D L Morris; P W Dillon; D L Very; P Ng; L Kish; J L Goldblatt; D J Bruzek; D W Chan; M S Ahmed; D Witek; H A Fritsche; C Smith; D Schwartz; M K Schwartz; J L Noteboom; R L Vessella; K K Yeung; W J Allard
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 4.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

5.  Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen.

Authors:  Magnus Jonsson; Sara Linse; Birgitta Frohm; Ake Lundwall; Johan Malm
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

6.  An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.

Authors:  Yafei Hou; Jason DeVoss; Vinh Dao; Serena Kwek; Jeffrey P Simko; Douglas G McNeel; Mark S Anderson; Lawrence Fong
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

7.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen.

Authors:  H Lilja; J Oldbring; G Rannevik; C B Laurell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

8.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

Authors:  H J Dubbink; N S Verkaik; P W Faber; J Trapman; F H Schröder; J C Romijn
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

9.  Semenogelins in the human retina: Differences in distribution and content between AMD and normal donor tissues.

Authors:  Vera L Bonilha; Mary E Rayborn; Karen G Shadrach; Yong Li; Ake Lundwall; Johan Malm; Joe G Hollyfield
Journal:  Exp Eye Res       Date:  2007-10-25       Impact factor: 3.467

10.  The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins.

Authors:  Anneli M L Edström; Johan Malm; Birgitta Frohm; Julie A Martellini; Aleksander Giwercman; Matthias Mörgelin; Alexander M Cole; Ole E Sørensen
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.